{"success":true,"data":{"pressRelease":{"id":"19902","rtpr_id":"nACS4fJDva","ticker":"ALDX","exchange":"NASDAQ","all_tickers":["ALDX"],"title":"Pomerantz LLP Issues Important Reminder to Aldeyra Therapeutics, Inc.  Shareholders – ALDX","author":"ACCESSWIRE","published_at":"2026-05-04T22:00:01.127Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 4,\n2026 / Pomerantz LLP announces that a class action lawsuit has been filed\nagainst Aldeyra Therapeutics, Inc. (\"Aldeyra\" or the \"Company\")\n(NASDAQ:ALDX).   Such investors are advised to contact Danielle Peyton at\nnewaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980.\nThose who inquire by e-mail are encouraged to include their mailing address,\ntelephone number, and the number of shares purchased.\n\nThe class action concerns whether Aldeyra and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\nYou have until May 29, 2026, to ask the Court to appoint you as Lead Plaintiff\nfor the class if you purchased or otherwise acquired Aldeyra securities during\nthe Class Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.        \n\n[Click here for information about joining the class action]\n(https://pomlaw.com/learn-more-form?company=ALDX)\n\nOn March 17, 2026, Aldeyra issued a press release \"announcing receipt of a\nComplete Response Letter (CRL) from the U.S. Food and Drug Administration\n(FDA) for the New Drug Application (NDA) of reproxalap, an investigational\ndrug candidate, for the treatment of dry eye disease.\" According to Aldeyra's\npress release, \"[t]he CRL stated that there is ‘a lack of substantial\nevidence consisting of adequate and well-controlled investigations ... that\nthe drug product will have the effect it purports or is represented to have\nunder the conditions of use prescribed, recommended, or suggested in its\nproposed labeling' and that ‘the application has failed to demonstrate\nefficacy in adequate and well controlled studies in the treatment of signs and\nsymptoms of dry eye disease.' The letter also stated that the ‘inconsistency\nof study results raises serious concerns about the reliability and\nmeaningfulness of the positive findings' and that the ‘totality of evidence\nfrom the completed clinical trials does not support the effectiveness of the\nproduct.'\"\n\nOn this news, Aldeyra's stock price fell $2.99 per share, or 70.69%, to close\nat $1.24 per share on March 17, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising.  Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-issues-important-reminder-to-aldeyra-therapeutics-1153820)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACS4fJDva","title":"Pomerantz LLP Issues Important Reminder to Aldeyra Therapeutics, Inc.  Shareholders – ALDX","author":"ACCESSWIRE","ticker":"ALDX","created":"2026-05-04T22:00:01.127Z","tickers":["ALDX"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 4,\n2026 / Pomerantz LLP announces that a class action lawsuit has been filed\nagainst Aldeyra Therapeutics, Inc. (\"Aldeyra\" or the \"Company\")\n(NASDAQ:ALDX).   Such investors are advised to contact Danielle Peyton at\nnewaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980.\nThose who inquire by e-mail are encouraged to include their mailing address,\ntelephone number, and the number of shares purchased.\n\nThe class action concerns whether Aldeyra and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\nYou have until May 29, 2026, to ask the Court to appoint you as Lead Plaintiff\nfor the class if you purchased or otherwise acquired Aldeyra securities during\nthe Class Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.        \n\n[Click here for information about joining the class action]\n(https://pomlaw.com/learn-more-form?company=ALDX)\n\nOn March 17, 2026, Aldeyra issued a press release \"announcing receipt of a\nComplete Response Letter (CRL) from the U.S. Food and Drug Administration\n(FDA) for the New Drug Application (NDA) of reproxalap, an investigational\ndrug candidate, for the treatment of dry eye disease.\" According to Aldeyra's\npress release, \"[t]he CRL stated that there is ‘a lack of substantial\nevidence consisting of adequate and well-controlled investigations ... that\nthe drug product will have the effect it purports or is represented to have\nunder the conditions of use prescribed, recommended, or suggested in its\nproposed labeling' and that ‘the application has failed to demonstrate\nefficacy in adequate and well controlled studies in the treatment of signs and\nsymptoms of dry eye disease.' The letter also stated that the ‘inconsistency\nof study results raises serious concerns about the reliability and\nmeaningfulness of the positive findings' and that the ‘totality of evidence\nfrom the completed clinical trials does not support the effectiveness of the\nproduct.'\"\n\nOn this news, Aldeyra's stock price fell $2.99 per share, or 70.69%, to close\nat $1.24 per share on March 17, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising.  Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-issues-important-reminder-to-aldeyra-therapeutics-1153820)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-04T22:00:01.166941656Z","server_sent_at_ms":1777932001166},"received_at":"2026-05-04T22:00:01.606Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-issues-important-reminder-to-aldeyra-therapeutics-1153820"},"analysis":{"id":"14585","press_release_id":"19902","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Pomerantz LLP issued a reminder to Aldeyra Therapeutics investors regarding a filed class action lawsuit.\n\nThe suit alleges securities fraud connected to the FDA's Complete Response Letter for reproxalap issued in March 2026.\n\nThis release is a standard law-firm solicitation for lead plaintiffs and does not constitute new corporate disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Danielle Peyton","role":"Contact at Pomerantz LLP"}],"products":["reproxalap"],"companies":[{"name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","relationship":"target"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$2.99 per share","context":"stock price decline on March 17, 2026"},{"amount":"$1.24 per share","context":"closing stock price on March 17, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Pomerantz LLP. No new disclosure from the issuer; this is a class-action reminder and lead-plaintiff deadline notice, which is treated as low-signal noise."},"tickerRelevance":{"others":[],"primary":"ALDX"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEventSeverity":"fda_rejection"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Pomerantz LLP issued a reminder to Aldeyra Therapeutics investors regarding a filed class action lawsuit.\n\nThe suit alleges securities fraud connected to the FDA's Complete Response Letter for reproxalap issued in March 2026.\n\nThis release is a standard law-firm solicitation for lead plaintiffs and does not constitute new corporate disclosure.","key_figures":{},"named_entities":{"people":[{"name":"Danielle Peyton","role":"Contact at Pomerantz LLP"}],"products":["reproxalap"],"companies":[{"name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","relationship":"target"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$2.99 per share","context":"stock price decline on March 17, 2026"},{"amount":"$1.24 per share","context":"closing stock price on March 17, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T22:13:36.619Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEventSeverity":"fda_rejection"}},"durationMs":14964,"modelName":"glm-4.7"}}